Nektar Therapeutics (NASDAQ:NKTR) shares, rose in value on Wednesday, March 26, with the stock price down by -4.26% to the previous day’s close as strong demand from buyers drove the stock to $0.80.
Actively observing the price movement in the last trading, the stock closed the session at $0.84, falling within a range of $0.7522 and $0.8352. The value of beta (5-year monthly) was 0.655. Referring to stock’s 52-week performance, its high was $1.93, and the low was $0.65. On the whole, NKTR has fluctuated by -7.91% over the past month.
With the market capitalization of Nektar Therapeutics currently standing at about $149.18 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-11.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 15.61M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NKTR’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of NKTR currently trading nearly -5.55% and -5.77% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.63, while the 7-day volatility ratio is showing 9.79% which for the 30-day chart, stands at 9.76%. Furthermore, Nektar Therapeutics (NKTR)’s beta value is 0.62, and its average true range (ATR) is 0.08.
A comparison of Nektar Therapeutics (NKTR) with its peers suggests the former has fared considerably weaker in the market. NKTR showed an intraday change of -4.26% in last session, and over the past year, it shrunk by -12.25%%.
Data on historical trading for Nektar Therapeutics (NASDAQ:NKTR) indicates that the trading volumes over the past 10 days have averaged 1.48 and over the past 3 months, they’ve averaged 2.01 million. According to company’s latest data on outstanding shares, there are 185.78 million shares outstanding.
Nearly 3.62% of Nektar Therapeutics’s shares belong to company insiders and institutional investors own 69.48% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.95 million shares as on 2025-03-14, resulting in a short ratio of 3.38. According to the data, the short interest in Nektar Therapeutics (NKTR) stood at 476.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 7.48 million. The stock has fallen by -13.81% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NKTR stock heading into the next quarter.
